Drug Trial Radar · NCT04943848
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jan 10, 2022
Primary completion
Sep 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Dana-Farber Cancer Institute; Children's Hospital of Orange County; University of Calgary
- First posted
- Jun 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
Conditions
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
rHSC-DIPGVaxBiological
Off-the-shelf, neoantigen heat shock protein vaccine
BalstilimabDrug
BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
ZalifrelimabDrug
ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVaxTime frame: DLT period of 28 days for rHSC-DIPGVax monotherapy
- Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVax plus BALSTILIMABTime frame: DLT period of 28 days for Part A
- Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVax plus BALSTILIMAB and ZALIFRELIMABTime frame: DLT period of 42 days for Part B
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Children's Health Orange County (CHOC)
Orange, California · Recruiting
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Dana-Farber Boston Children's Cancer and Blood Disorders Center
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.